Enbrel (Etanercept) Market Report 2026

Enbrel (Etanercept) Market Overview

• The Enbrel (Etanercept) market growth in the historic period has been driven by increasing prevalence of autoimmune disorders, availability of biologic treatment options • Market expansion is supported by increasing competition from biosimilars, rising demand for cost-effective biologic therapies • Growth Driver: Growing Prevalence Of Autoimmune Conditions To Drive Enbrel (Etanercept) Market Growth • Market Trend: Advancements In Enbrel (Etanercept) And The TNF Inhibitor Market For Autoimmune Disease Management • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Enbrel (Etanercept) Market?

Enbrel (etanercept) is a biologic medication used to treat various autoimmune conditions by inhibiting the activity of tumor necrosis factor (TNF), a protein that plays a key role in inflammation. It is a synthetic form of a naturally occurring protein in the body, designed to bind to TNF and prevent it from binding to its receptors, thereby reducing inflammation. It is typically administered via subcutaneous injection, either by a healthcare provider or by patients themselves at home. The main types of enbrel (etanercept) include brand drugs and biosimilar drugs. Enbrel is a biologic medication containing etanercept, used to treat autoimmune conditions such as rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis by inhibiting tumor necrosis factor (TNF). It has both liquid solution and powder for injection forms and is applied for rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and juvenile idiopathic arthritis.

What Is The Enbrel (Etanercept) Market Growth Forecast?

The enbrel (etanercept) market size is expected to see strong growth in the next few years. It will grow to $23.64 million in 2030 at a compound annual growth rate (CAGR) of 5.9%. The growth in the forecast period can be attributed to increasing competition from biosimilars, rising demand for cost-effective biologic therapies, expansion of home-based treatment models, growing focus on value-based healthcare, increasing innovation in biologic drug delivery systems. Major trends in the forecast period include increasing adoption of biosimilar tnf inhibitors, rising focus on patient self-administration devices, growing use of long-term maintenance therapy, expansion of autoimmune disease indications, enhanced emphasis on treatment adherence.

Global Enbrel (Etanercept) Market Segmentation

1) By Product: Branded Drugs, Biosimilar Drugs 2) By Form: Liquid Solution, Powder For Injections 3) By Application: Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, Juvenile Idiopathic Arthritis

What Is The Driver Of The Enbrel (Etanercept) Market?

The surging prevalence of autoimmune conditions is expected to propel the growth of the enbrel (etanercept) market going forward. Autoimmune conditions occur when the immune system erroneously targets and attacks the body's own healthy tissues. The rising prevalence of autoimmune conditions is driven by factors such as genetic susceptibility, the hygiene hypothesis, environmental triggers, and improved diagnosis and awareness. Enbrel is effective in treating various autoimmune disorders, such as rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and plaque psoriasis. It works by inhibiting tumor necrosis factor-alpha (TNF-α), a crucial protein in immune and inflammatory responses, thereby reducing inflammation, alleviating symptoms, and slowing the progression of these conditions. For instance, in June 2024, according to data published by the Australian Institute of Health and Welfare, an Australia-based national agency for information and statistics, in 2022, about 514,000 Australians (2.0%) were living with rheumatoid arthritis, which represented 2.0% of the total disease burden and 16% of the musculoskeletal disease burden in 2023. It also contributed to 1,322 deaths (5.1 per 100,000), making up 0.7% of all deaths. Therefore, the surging prevalence of autoimmune conditions will drive the growth of the enbrel (etanercept) industry going forward.

Key Players In The Global Enbrel (Etanercept) Market

Major companies operating in the enbrel (etanercept) market are Amgen Inc, Pfizer Inc.

Global Enbrel (Etanercept) Market Trends and Insights

Major companies operating in the enbrel (etanercept) market is developing innovative products, such as TNF inhibitors, to reduce inflammation and immune system activity. A TNF inhibitor is a biologic treatment that targets and blocks tumor necrosis factor (TNF), a protein that plays a key role in inflammation, to help manage autoimmune diseases. For instance, in October 2023, Amgen Inc., a US-based biotechnology company, announced the U.S. Food and Drug Administration approval for Enbrel (etanercept) for the management of children aged two and up who have active juvenile psoriatic arthritis (JPsA). The biologic medication is used to treat autoimmune conditions such as rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and plaque psoriasis. It works by blocking tumor necrosis factor (TNF), a protein that triggers inflammation and immune responses, helping to alleviate symptoms such as joint swelling and pain. Administered through a weekly subcutaneous injection, Enbrel can be used alone or with other medications such as methotrexate.

What Are Latest Mergers And Acquisitions In The Enbrel (Etanercept) Market?

In December 2023, Intas Pharmaceuticals Ltd., an India-based pharmaceutical company that manufactures biosimilar drugs for etanercept, entered into an exclusive licensing agreement with mAbxience for the commercialization of an etanercept biosimilar. Through this collaboration, Intas aims to strengthen its global biosimilar portfolio and expand access to high-quality treatments for autoimmune diseases across more than 150 countries, including major markets such as Europe and the United States. mAbxience is a Spain-based company specializing in the development, production, and commercialization of biopharmaceuticals.

Regional Insights

North America was the largest region in the enbrel (etanercept) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

What Defines the Enbrel (Etanercept) Market?

The enbrel (etanercept) market consists of sales of injections, cooler packs, reconstitution kit and related products. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Enbrel (Etanercept) Market Report 2026?

The enbrel (etanercept) market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the enbrel (etanercept) industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.